Shares of Seres Therapeutics Inc (NASDAQ:MCRB) have received an average rating of “Buy” from the nine brokerages that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $5.17.
Several research analysts recently issued reports on MCRB shares. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Thursday, July 4th. Chardan Capital reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, June 17th. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Jefferies Financial Group cut their price target on Seres Therapeutics from $6.00 to $4.00 and set a “hold” rating for the company in a report on Monday, July 1st. Finally, BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 22nd.
NASDAQ MCRB traded up $0.08 during trading hours on Thursday, reaching $3.74. The company’s stock had a trading volume of 334,437 shares, compared to its average volume of 415,646. The stock has a market cap of $261.48 million, a PE ratio of -1.54 and a beta of 1.79. Seres Therapeutics has a fifty-two week low of $2.02 and a fifty-two week high of $9.00. The company’s 50-day moving average is $3.18 and its two-hundred day moving average is $4.44.
Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.17. The business had revenue of $12.53 million for the quarter, compared to analysts’ expectations of $10.29 million. As a group, equities research analysts forecast that Seres Therapeutics will post -1.45 earnings per share for the current year.
In other news, Director Noubar Afeyan purchased 8,888,888 shares of the stock in a transaction dated Tuesday, June 18th. The stock was acquired at an average cost of $2.25 per share, for a total transaction of $19,999,998.00. Following the completion of the acquisition, the director now directly owns 15,141 shares in the company, valued at approximately $34,067.25. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 37.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA grew its stake in Seres Therapeutics by 945.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,339 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 3,924 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Seres Therapeutics by 3,656.7% during the second quarter. Tower Research Capital LLC TRC now owns 8,678 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 8,447 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Seres Therapeutics during the second quarter worth $34,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Seres Therapeutics in the second quarter valued at $42,000. Finally, DekaBank Deutsche Girozentrale grew its position in shares of Seres Therapeutics by 21.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 19,800 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 3,500 shares during the period. Hedge funds and other institutional investors own 88.01% of the company’s stock.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).
Recommended Story: Economic Reports
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.